Is ABOS or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer ABOS or ALLO?

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 1 mentions for Allogene Therapeutics. Acumen Pharmaceuticals' average media sentiment score of -0.24 beat Allogene Therapeutics' score of -1.74 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Does the media favor OCS or ABOS?

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 3 mentions for Oculis. Oculis' average media sentiment score of 0.00 beat Acumen Pharmaceuticals' score of -0.24 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, AURA or ABOS?

Aura Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is AURA or ABOS more profitable?

Aura Biosciences' return on equity of -78.12% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media prefer AURA or ABOS?

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat Acumen Pharmaceuticals' score of -0.24 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ABOS or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is ABOS or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Climb Bio N/A -31.45% -30.39%

Does the media prefer ACRS or ABOS?

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.36 beat Acumen Pharmaceuticals' score of -0.24 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Acumen Pharmaceuticals (ABOS) Competitors

$2.41 +0.01 (+0.42%)

As of 06/23/2026 04:00 PM Eastern

Compare

ABOS vs. ALLO, OCS, AURA, CLYM, and ACRS

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Allogene Therapeutics (ALLO), Oculis (OCS), Aura Biosciences (AURA), Climb Bio (CLYM), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Acumen Pharmaceuticals currently has a consensus target price of $8.00, indicating a potential upside of 231.95%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 311.70%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Allogene Therapeutics' return on equity of -56.45% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 1 mentions for Allogene Therapeutics. Acumen Pharmaceuticals' average media sentiment score of -0.24 beat Allogene Therapeutics' score of -1.74 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Acumen Pharmaceuticals has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Allogene Therapeutics	$20K	35,723.03	-$190.89M	-$0.77	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

Allogene Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Oculis?

Oculis (NASDAQ:OCS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 3 mentions for Oculis. Oculis' average media sentiment score of 0.00 beat Acumen Pharmaceuticals' score of -0.24 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis has higher revenue and earnings than Acumen Pharmaceuticals. Oculis is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	468.64	-$119.44M	-$2.13	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Oculis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

22.3% of Oculis shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oculis currently has a consensus target price of $38.33, suggesting a potential upside of 227.08%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 231.95%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Acumen Pharmaceuticals beats Oculis on 8 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Aura Biosciences' return on equity of -78.12% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat Acumen Pharmaceuticals' score of -0.24 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Aura Biosciences currently has a consensus target price of $20.50, indicating a potential upside of 192.02%. Acumen Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 231.95%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aura Biosciences beats Acumen Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Climb Bio?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Climb Bio	N/A	-31.45%	-30.39%

In the previous week, Acumen Pharmaceuticals had 5 more articles in the media than Climb Bio. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 0 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.00 beat Acumen Pharmaceuticals' score of -0.24 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Neutral
Climb Bio	Neutral

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 231.95%. Climb Bio has a consensus target price of $21.73, indicating a potential upside of 76.64%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Summary

Climb Bio beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.36 beat Acumen Pharmaceuticals' score of -0.24 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Aclaris Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	87.76	-$64.92M	-$0.56	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 133.74%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 231.95%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Acumen Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$173.35M	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.30	19.75	24.67	23.99
Price / Sales	N/A	330.65	528.41	106.93
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.08	8.29	10.76	6.50
Net Income	-$121.33M	$23.85M	$3.56B	$336.88M
7 Day Performance	7.11%	2.87%	1.03%	-0.14%
1 Month Performance	-3.98%	2.19%	0.45%	0.77%
1 Year Performance	91.27%	55.48%	29.69%	28.49%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.199 of 5 stars	$2.41 +0.4%	$8.00 +232.0%	+95.9%	$173.35M	N/A	N/A	20
ALLO Allogene Therapeutics	2.3622 of 5 stars	$1.96 +0.8%	$8.52 +335.9%	+69.7%	$671.32M	$20K	N/A	310
OCS Oculis	2.8349 of 5 stars	$11.42 -1.6%	$38.33 +235.6%	-40.4%	$662.71M	$1.45M	N/A	2	Gap Down
AURA Aura Biosciences	2.5327 of 5 stars	$6.28 -2.7%	$20.50 +226.7%	+14.1%	$647.74M	N/A	N/A	50	Gap Down
CLYM Climb Bio	3.1751 of 5 stars	$11.08 -3.6%	$21.73 +96.1%	+925.0%	$630.89M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. ALLO, OCS, AURA, CLYM, and ACRS

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Oculis?

Summary

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Summary

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. ALLO, OCS, AURA, CLYM, and ACRS

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Do analysts recommend ABOS or ALLO?

Is ABOS or ALLO more profitable?

Does the media prefer ABOS or ALLO?

Which has better earnings and valuation, ABOS or ALLO?

Do insiders & institutionals have more ownership in ABOS or ALLO?

Which has more volatility & risk, ABOS or ALLO?

Summary

How does Acumen Pharmaceuticals compare to Oculis?

Is OCS or ABOS more profitable?

Does the media favor OCS or ABOS?

Which has better earnings and valuation, OCS or ABOS?

Which has more risk and volatility, OCS or ABOS?

Do institutionals & insiders believe in OCS or ABOS?

Do analysts rate OCS or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Is AURA or ABOS more profitable?

Does the media prefer AURA or ABOS?

Which has better valuation and earnings, AURA or ABOS?

Do analysts prefer AURA or ABOS?

Which has more risk and volatility, AURA or ABOS?

Do insiders and institutionals have more ownership in AURA or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Do insiders and institutionals believe in ABOS or CLYM?

Is ABOS or CLYM more profitable?

Does the media refer more to ABOS or CLYM?

Which has more volatility and risk, ABOS or CLYM?

Do analysts recommend ABOS or CLYM?

Which has better earnings and valuation, ABOS or CLYM?

Summary

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Does the media prefer ACRS or ABOS?

Do insiders & institutionals hold more shares of ACRS or ABOS?

Is ACRS or ABOS more profitable?

Which has stronger valuation and earnings, ACRS or ABOS?

Do analysts recommend ACRS or ABOS?

Which has more volatility & risk, ACRS or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools